MCTL THERAPY FOR
GASTRIC CANCER
Understanding how MCTL cell therapy is being explored for advanced gastric cancer, who may benefit, and what patients should consider before pursuing this approach in China.
analyticsAt a Glance
- check_circleInvestigational — offered at select Chinese centres
- check_circleTrains T cells against multiple gastric cancer antigens
- check_circleMay be combined with toripalimab or standard therapy
- check_circleFull specialist review required before eligibility assessment
Why Gastric Cancer Patients Explore MCTL
Gastric cancer remains one of the most common and aggressive cancers worldwide, particularly in East Asia. For patients whose disease progresses after first-line treatment, standard options offer modest survival benefits.
Limited Second-Line Options
After progression on FOLFOX, FLOT, or platinum-based regimens, second-line options — ramucirumab, taxanes, irinotecan-based regimens — offer limited median OS benefits of a few months in most patients.
Immune Biology of Gastric Cancer
A subset of gastric cancers are EBV-positive or MSI-high, which respond well to checkpoint inhibitors. For HER2-negative, MSS, or immunotherapy-refractory disease, multi-target T-cell approaches are being explored.
Who May Be Considered for MCTL in Gastric Cancer
MCTL may be discussed after progression on available standard therapies. Eligibility requires structured specialist review.
Stage III–IV or Metastatic Gastric Cancer
Progressed after first-line or second-line chemotherapy, targeted therapy, or immunotherapy.
HER2-Negative or Post-Trastuzumab
HER2-positive patients who have received trastuzumab and progressed, and HER2-negative patients without available targeted options.
Adequate Organ Function and Performance Status
ECOG 0–2, adequate CBC, liver and kidney function. Rapidly progressive disease may not allow time for cell manufacturing.
Documents Needed for Gastric Cancer MCTL Review
| Document | Details Required |
|---|---|
| Pathology / biopsy report | Histology, Lauren classification, HER2 status (IHC/FISH), PD-L1 CPS score, EBV status, MMR/MSI |
| Endoscopy / staging reports | Most recent endoscopy, staging CT or PET-CT (within 4–6 weeks) |
| Treatment history | All regimens, cycle counts, responses, reason for stopping |
| Blood tests | CBC, LFT, RFT, CEA, CA72-4, CA19-9, infection markers |
| NGS / molecular testing | KRAS, NRAS, BRAF, PIK3CA, FGFR2, TROP2 expression where available |
Frequently Asked Questions
Related MCTL Resources
How CancerFax Helps
CancerFax is a specialist cancer access and patient-navigation platform. We help patients and families understand their options, organise medical records, coordinate hospital communication, and support cross-border treatment planning where appropriate.
We help collect and organise reports, scans, pathology, biomarker results, and treatment history for structured case review.
We communicate with hospitals or trial teams to assess whether a case may be suitable for further screening.
We support appointment coordination, document submission, translation, and direct communication with international departments.
For international patients, we help with practical coordination — travel planning, hospital admission guidance, and local support.
If this option is not suitable, we help explore other relevant treatments, clinical trials, or advanced care pathways.
From inquiry through to follow-up, our coordinators provide a single point of contact for the family.
CancerFax does not guarantee treatment access, eligibility, or clinical outcome. Our role is to help patients access accurate information, structured review, and appropriate specialist pathways.
Exploring Options for Advanced Gastric Cancer?
CancerFax reviews your full medical file and helps you understand whether MCTL or another advanced treatment pathway is a realistic next step after standard gastric cancer therapy.
This content is for informational purposes only and does not constitute medical advice. Always consult a qualified oncologist before making treatment decisions.